SMMT - Summit Therapeutics PLC

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America, and Europe. The company is headquartered in Cambridge, Massachusetts.

52W High

$36.91

52W Low

$15.55

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-1.03

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-5.32

EV/Revenue (<3 favorable)

6425.28

P/S (TTM) (<3 favorable)

753.90

P/B (<3 favorable)

74.39

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

84.30%

Institutions (25–75% balanced)

13.56%

Shares Outstanding

742,847,000

Float

116,181,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

705,000

EPS (TTM)

-1.01

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-3.28%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-1.00

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—